A Non-randomised, Open-label, Sequential, Multicentre, Two-part, Phase I Study to Assess the Effect of Rifampicin, a CYP Inducer, on the Pharmacokinetics of Olaparib Following Oral Dosing of a Tablet Formulation in Patients With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2017
Price : $35 *
At a glance
- Drugs Olaparib (Primary) ; Rifampicin
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 13 Jan 2017 Status changed from active, no longer recruiting to completed.
- 10 Oct 2016 Results assessing effect of rifampicin on pharmacokinetics of olaparib (n=22) published in the Clinical Therapeutics.
- 02 Jun 2015 Results assessing pharmacokinetics of olaparib in presence of rifampin presented at the 51st Annual Meeting of the American Society of Clinical Oncology.